Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW OKs Pfizer’s Jzoloft for PTSD Indication, Other Drugs
March 23, 2015
- 196 “Designated Intractable Diseases” Likely to Be Eligible for Subsidies from July
March 20, 2015
- Physicians Becoming Picky about Generic Brands: Survey
March 19, 2015
- Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
- Japan to Build Dementia Patients Registration System: WHO Ministerial Conference
March 19, 2015
- Chuikyo Approves Reimbursement for RAS Gene Test Kit; Listing Scheduled for April
March 19, 2015
- Chuikyo Approves Listing of ViiV Healthcare’s HIV Treatment Triumeq; Listing Scheduled for March 25
March 19, 2015
- MHLW to Urge Insurers to Promote Generic Use among Beneficiaries of High-Cost Healthcare Benefit System
March 18, 2015
- Govt Panel Members Push Deregulation of Bungyo Rules
March 16, 2015
- Govt Denies Intentional Falsification of Data in J-ADNI Study
March 16, 2015
- Prime Minister Abe Indicates the Need to Promote the Use of Biosimilars
March 16, 2015
- 70 Institutions Picked to Treat Post-HPV Vaccine Adverse Reactions
March 13, 2015
- PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
March 13, 2015
- PMDA Adopts FY2015 Project Plan Calling for Sped-Up Review
March 12, 2015
- Japan Generic Share Little over 50% If In-House Prescriptions Included: Official
March 11, 2015
- Mandatory CDISC-Based Submissions to Begin in October 2016
March 11, 2015
- Panel OKs 44 More Diseases as Designated Intractable Diseases
March 10, 2015
- MHLW to Target 75% Generic Share for Welfare Recipients
March 10, 2015
- MHLW’s Panel on Orphan Cancer Holds First Meeting; Draft Report Expected This Summer
March 10, 2015
- Editor’s Pick: Five Healthcare News Headlines for Feb. 23 - March 8
March 9, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…